Foto

Oppenheimer Analysts Give BioMarin Pharmaceutical (BMRN) a $92.00 Price Target

Oppenheimer set a $92.00 price target on BioMarin Pharmaceutical (NASDAQ:BMRN) in a research report released on Tuesday. The brokerage currently has a hold rating on the biotechnology company’s stock. Oppenheimer also issued estimates for BioMarin Pharmaceutical’s FY2018 earnings at ($0.33) EPS.

BMRN has been the topic of several other research reports. Wedbush set a $127.00 price objective on BioMarin Pharmaceutical and gave the company a buy rating in a report on Wednesday, November 14th. Cantor Fitzgerald set a $126.00 price objective on BioMarin Pharmaceutical and gave the company a buy rating in a report on Sunday, October 7th. Cowen reissued a buy rating on shares of BioMarin Pharmaceutical in a report on Monday, January 7th. Zacks Investment Research downgraded BioMarin Pharmaceutical from a buy rating to a hold rating in a report on Monday, December 31st. Finally, Wolfe Research started coverage on BioMarin Pharmaceutical in a report on Friday, December 14th. They set an outperform rating on the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $113.38.

Get BioMarin Pharmaceutical alerts: Shares of NASDAQ BMRN traded up $0.52 during mid-day trading on Tuesday, hitting $94.46. 659,866 shares of the stock traded hands, 1,044,758. The company has a quick ratio of 2.26, a current ratio of 2.87 and a debt-to-equity ratio of 0.28. BioMarin Pharmaceutical has a twelve month low of $75.81 and a twelve month high of $106.74. The company has a market cap of $16.18 billion, a price-to-earnings ratio of -140.99 and a beta of 1.57.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, October 25th. The biotechnology company reported ($0.07) quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.15. BioMarin Pharmaceutical had a negative return on equity of 2.98% and a negative net margin of 8.35%. The company had revenue of $391.71 million for the quarter, compared to the consensus estimate of $369.43 million. On average, research analysts anticipate that BioMarin Pharmaceutical will post -0.13 current fiscal year.

In other news, CEO Jean Jacques Bienaime sold 4,000 shares of the business’s stock in a transaction dated Wednesday, December 26th. The stock was sold at an average price of $80.50, for a total value of $322,000.00. Following the transaction, the chief executive officer now directly owns 292,290 shares of the company’s stock, valued at approximately $23,529,345. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, Director V Bryan Lawlis sold 2,150 shares of the business’s stock in a transaction dated Thursday, December 27th. The shares were sold at an average price of $82.53, for a total value of $177,439.50. Following the completion of the transaction, the director now directly owns 21,310 shares in the company, valued at $1,758,714.30. The disclosure for this sale can be found here . Insiders have sold a total of 35,150 shares of company stock worth $3,109,140 over the last ninety days. Company insiders own 1.90% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Nordea Investment Management AB lifted its stake in shares of BioMarin Pharmaceutical by 2.1% in the 3rd quarter. Nordea Investment Management AB now owns 7,206 shares of the biotechnology company’s stock valued at $699,000 after purchasing an additional 147 shares during the period. State of Alaska Department of Revenue lifted its stake in shares of BioMarin Pharmaceutical by 0.8% in the 4th quarter. State of Alaska Department of Revenue now owns 21,807 shares of the biotechnology company’s stock valued at $1,856,000 after purchasing an additional 175 shares during the period. Morningstar Investment Services LLC lifted its stake in shares of BioMarin Pharmaceutical by 11.8% in the 3rd quarter. Morningstar Investment Services LLC now owns 5,058 shares of the biotechnology company’s stock valued at $490,000 after purchasing an additional 532 shares during the period. Comerica Bank lifted its stake in shares of BioMarin Pharmaceutical by 5.9% in the 3rd quarter. Comerica Bank now owns 10,096 shares of the biotechnology company’s stock valued at $1,012,000 after purchasing an additional 565 shares during the period. Finally, Virtus ETF Advisers LLC lifted its stake in shares of BioMarin Pharmaceutical by 7.2% in the 3rd quarter. Virtus ETF Advisers LLC now owns 8,700 shares of the biotechnology company’s stock valued at $844,000 after purchasing an additional 586 shares during the period.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Further Reading: How to Invest in a Bull Market

BioMarin Pharmaceutical BioMarin Pharmaceutical